Therapeutic Effect and Mechanism of Targeted Nano-selenium in Mouse Model of Parkinson’s Disease Induced by MPTP
Objective: In the present study, we developed a nanozyme (Se@PB-ACPP) incorporating selenium-loaded Prussian blue (PB) and modified it with an activatable cell-penetrating peptide (ACPP) to…Prodromal Parkinson’s Disease in Agent Orange Exposed US Vietnam Veterans
Objective: 1-Comparing the risk of prodromal PD between AO exposed veterans (AOEV) and non-AO exposed veterans without PD (Controls) in a Veterans Affairs (VA) hospital…GCase and Ganglioside GM1 Interaction in Parkinson’s Disease
Objective: The project aims to further understand the role of the ganglioside GM1 in the relationship between GBA1 mutations and higher α-synuclein levels. Background: Among…PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA
Objective: To assess the effect of KM-819 on the progression of multiple system atrophy (MSA). Background: Parkinson’s brain is associated with increased expression of the…Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study
Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience
Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial
Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.
Objective: The objective of the present study is focused on the design and synthesis of 16-pyridyl methylene derivatives of steroidal oximes and further their pharmacological…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »